By Fineline Cube 
China-based Consun Pharmaceutical Group Ltd (HKG: 1681) announced a strategic partnership with compatriot firm DP Technology to enhance the research and development (R&D) of drugs targeting kidney diseases through the application of artificial intelligence (AI).
Leveraging AI for Nephrology Advancements
Consun Pharma, a leader in nephrology, medical imaging, and women/children’s health therapeutics, brings extensive expertise in novel drug development and technology integration. DP Technology, a global pioneer in AI for scientific applications, contributes core competencies in AI-powered drug discovery, smart lab solutions, and the modernization of traditional Chinese medicine (TCM).
Collaboration Framework
Under the agreement, the two parties will engage in deep collaboration across innovative target and drug discovery, target mechanism research, process optimization, intelligent laboratory development, and TCM modernization. The partnership aims to integrate industrial advantages in drug R&D, manufacturing, and market presence through ecological co-creation and complementary strengths. This collaborative effort seeks to advance AI-driven drug R&D and elevate industrial quality.-Fineline Info & Tech